MONROVIA, Calif.--(BUSINESS WIRE)--May 8, 2019--
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company
developing engineered monoclonal antibodies for the treatment of cancer,
autoimmune disease, asthma and allergic diseases, today announced that
company management will present at two upcoming conferences:
- Bank of America Merrill Lynch 2019 Health Care Conference
Wednesday, May 15, 2019
Location: Las Vegas, NV
Time: 4:20 p.m. PT
- Berenberg Conference USA 2019
Date: Wednesday, May
Location: Tarrytown, NY
Time: 9:45 a.m. ET
A live webcast of the Bank of America Merrill Lynch conference will be
available under "Events & Presentations" in the Investors section of the
Company's website located at https://investors.xencor.com/events.cfm.
A replay of the event will be posted on the Xencor website approximately
one hour after the live event and will be available for 90 days
following the event.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing
engineered monoclonal antibodies for the treatment of cancer, autoimmune
disease, asthma and allergic diseases. Currently, 13 candidates
engineered with Xencor's XmAb® technology are in
clinical development internally and with partners. Xencor's XmAb
antibody engineering technology enables small changes to the structure
of monoclonal antibodies resulting in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005748/en/
Source: Xencor, Inc.
Jason I. Spark